Immunic, Inc. IMUX

IMUX Company Overview

Immunic, Inc. (NASDAQ: IMUX) is a clinical-stage biotechnology company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company’s research and development efforts are concentrated on small-molecule therapies designed to modulate immune and metabolic pathways associated with diseases such as multiple sclerosis, psoriasis, ulcerative colitis, and other immune-mediated disorders. Immunic primarily operates within the biotechnology and pharmaceutical sectors, with its value proposition centered on orally administered therapies intended to offer improved safety, tolerability, and long-term disease management compared with some existing biologic treatments.

The company’s primary revenue driver remains capital raised through equity offerings and financing activities, as Immunic has not yet commercialized products generating recurring product revenue. Its core pipeline includes vidofludimus calcium (IMU-838), a selective immune modulator under clinical evaluation for relapsing multiple sclerosis and other inflammatory indications, along with IMU-856 and IMU-381, which target gastrointestinal barrier function and autoimmune disease pathways, respectively. Immunic traces its origins to the merger between Vital Therapies, Inc. and privately held Immunic AG in 2019, which repositioned the combined entity into an immunology-focused biotechnology company headquartered in the United States with scientific operations linked to Germany.